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The antidiabetic biguanide metformin exerts antiproliferative effects in different solid
tumors. However, during preclinical studies, metformin concentrations required to
induce cell growth arrest were invariably within the mM range, thus difficult to translate
in a clinical setting. Consequently, the search for more potent metformin derivatives
is a current goal for new drug development. Although several cell-specific intracellular
mechanisms contribute to the anti-tumor activity of metformin, the inhibition of the
chloride intracellular channel 1 activity (CLIC1) at G1/S transition is a key events in
metformin antiproliferative effect in glioblastoma stem cells (GSCs). Here we tested
several known biguanide-related drugs for the ability to affect glioblastoma (but not
normal) stem cell viability, and in particular: phenformin, a withdrawn antidiabetic drug;
moroxydine, a former antiviral agent; and proguanil, an antimalarial compound, all of
them possessing a linear biguanide structure as metformin; moreover, we evaluated
cycloguanil, the active form of proguanil, characterized by a cyclized biguanide moiety.
All these drugs caused a significant impairment of GSC proliferation, invasiveness,
and self-renewal reaching IC50 values significantly lower than metformin, (range
0.054–0.53 mM vs. 9.4 mM of metformin). All biguanides inhibited CLIC1-mediated
ion current, showing the same potency observed in the antiproliferative effects, with the
exception of proguanil which was ineffective. These effects were specific for GSCs, since
no (or little) cytotoxicity was observed in normal umbilical cord mesenchymal stem cells,
whose viability was not affected by metformin and moroxydine, while cycloguanil and
phenformin induced toxicity only at much higher concentrations than required to reduce
GSC proliferation or invasiveness. Conversely, proguanil was highly cytotoxic also for
normal mesenchymal stem cells. In conclusion, the inhibition of CLIC1 activity represents
a biguanide class-effect to impair GSC viability, invasiveness, and self-renewal, although
dissimilarities among different drugs were observed as far as potency, efficacy and
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selectivity as CLIC1 inhibitors. Being CLIC1 constitutively active in GSCs, this feature is
relevant to grant the molecules with high specificity toward GSCs while sparing normal
cells. These results could represent the basis for the development of novel biguanide-
structured molecules, characterized by high antitumor efficacy and safe toxicological
profile.
Keywords: glioblastoma, cancer stem cells, metformin, biguanides, proliferation, CLIC1
INTRODUCTION
Novel drug development is currently facing significant drawbacks
due to the increasing costs of preclinical screening and the
more stringent rules on drug safety adopted by government
agencies. Thus, a system already intrinsically inefficient (i.e.,
few molecules every year can be proved to perform better than
existing drugs) is now becoming economically unsustainable
(Paul et al., 2010; Avorn, 2015; Dovrolis et al., 2017). This is
particularly true for cancer treatment, where costs afforded for
the development of targeted therapies impede their availability
for all the potentially responsive patients. In this scenario, drug
repositioning (Langedijk et al., 2015; Sleire et al., 2017) represents
one of the new strategies used to maximize the efficiency of the
drug development process, allowing a faster and less expensive
bench-to-clinic translation, and to minimize risks of unexpected
toxicities (Kim et al., 2016; Nosengo, 2016; Wurth et al., 2016).
This approach is aimed to identify novel therapeutic indications
for drugs previously approved for different uses. In particular,
drugs, already gone through clinical trials, either currently in
clinical use for different diseases or discontinued for inefficacy on
their original indication, can be repurposed for novel therapeutic
approaches.
Glioblastoma (GBM, WHO grade IV astrocytoma) is a
rapidly growing brain tumor characterized by invasive and pro-
angiogenic behavior leading to poor prognosis (Brat et al., 2007;
Furnari et al., 2007; Louis et al., 2007). GBM is still an incurable
tumor and, notwithstanding the development of new treatments,
including a multimodal approach in which maximal safe surgery
is followed by radiotherapy and temozolomide as cytotoxic drug,
the median survival rate is still about only 15 months (Stupp et al.,
2009). In fact, due to the infiltrating nature, a complete surgical
resection of GBM is virtually impossible and the tumor rapidly
relapses. Other possible reasons responsible for the therapeutic
failure of GBM treatments involve anatomical issues (i.e., the
presence of the blood–brain barrier), the high neuronal toxicity
of treatments, and, more importantly, the presence of small
populations of cancer cells, named cancer stem cells (CSCs),
which are highly refractory to radiotherapy and cytotoxic drugs
(Vescovi et al., 2006; Lathia et al., 2011; Meyer et al., 2015). CSCs
play a primary role in the development and recurrence of most
of solid and hematological tumors including GBM. Typically,
but not always, CSCs are characterized by CD133 expression as
surface marker (Ludwig and Kornblum, 2017), and, similarly to
normal stem cells, persist within the tumor mass due to their self-
renew ability. CSCs are able to differentiate giving origin to all the
phenotypes composing the bulk of the different cell populations
within the tumor. Thus, the presence of CSCs confers great cell
heterogeneity to GBM and, importantly, resistance to chemo- and
radio-therapy involving different molecular mechanisms (Singh
et al., 2004; Florio and Barbieri, 2012; Park et al., 2018). In fact,
like normal stem cells, CSCs display high expression of DNA
repairing enzymes and drug eﬄux transporters. Recently, several
reports support the notion that GBM CSCs (GSCs) derive not
only from transformed neural stem or progenitor cells but also
from the de-differentiation of non-CSC “differentiated” tumor
cells in response to micro-environmental factors (Friedmann-
Morvinski, 2014; Suva et al., 2014). Therefore, CSCs are
nowadays considered the crucial players for the development
of several neoplastic diseases, including GBM, and represent
an elective target to obtain efficacious therapeutic responses.
However, to date, only few reports have identified, at a preclinical
level, a significant antitumor activity on human GSCs of known
or experimental drugs (Griffero et al., 2009; Gupta et al., 2009;
Sachlos et al., 2012; Carra et al., 2013; Triscott et al., 2015;
Angeletti et al., 2016), making this tumor cell population a
relevant target to test repositioned drugs. In recent years, several
molecules were repositioned as anticancer agents [i.e., disulfiram,
itraconazole, aspirin, sertraline, ritonavir, propranolol, among
others (Wurth et al., 2016)], but metformin is the best studied and
most promising drug candidate (Wurth et al., 2014; Chae et al.,
2016; Heckman-Stoddard et al., 2017; Romero et al., 2017).
Metformin is a biguanide derivative used as first-line drug for
treating type 2 diabetes. Currently, millions of people are treated
with metformin showing only minor adverse reactions. Starting
from epidemiologic studies, a potential chemopreventive effect
of metformin was identified in diabetic patients, demonstrating
a significant lower incidence of several solid tumors (Evans
et al., 2005). Following this evidence, numerous preclinical
studies demonstrated that metformin significantly reduce cell
proliferation in different in vitro and in vivo cancer models,
including breast (Hirsch et al., 2009; Barbieri et al., 2015;
Baldassari et al., 2018), prostate (Ben Sahra et al., 2011; Kato
et al., 2015), colon (Zaafar et al., 2014), neuroblastoma (Costa
et al., 2014), osteosarcoma (Gatti et al., 2016, 2018; Xu et al., 2017;
Paiva-Oliveira et al., 2018), and, relevant to this study, GBM (Sato
et al., 2012; Wurth et al., 2013; Yang et al., 2016; Kim et al., 2017).
Notably, while displaying toxic effects in several tumor cells,
metformin is basically harmless for normal stem cells (Wurth
et al., 2013; Gritti et al., 2014), confirming the safety profile of this
drug as observed after chronic use in diabetic patients. Similar
antitumor effects have also been reported for other structurally-
related biguanides, in particular phenformin and buformin (Zhu
et al., 2015; Jiang et al., 2016; Petrachi et al., 2017; Rajeshkumar
et al., 2017), two antidiabetic agents withdrawn from clinical
use due to the risk of lactic acidosis. Moreover, experimental
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biguanides, never tested in clinics, were reported to exert in vitro
antitumor activity in GBM and ovarian cancer cells (Choi et al.,
2016; Zhang et al., 2016).
Mechanistically, several different intracellular signals were
identified as potential mediators of metformin antitumor activity.
First, it was proposed that metformin causes the activation of
the AMP-activated protein kinase (AMPK), similarly to what
observed in liver to inhibit glucose release (Rena et al., 2017).
In turn, AMPK inhibits mTOR pathway causing cell growth
arrest (Foretz et al., 2014), although recent studies proposed
that, in GBM, the activation of AMPK could lead to increased
proliferation (Chhipa et al., 2018). However, several other
intracellular pathways endowed with a potential antiproliferative
activity are affected by metformin in tumor cells (i.e., Akt, STAT3,
miRNA deregulation, among others) (Bao et al., 2012; Wurth
et al., 2013; Feng et al., 2014). Moreover, metformin indirect
antitumor effects, such as the inhibition of the release or the
activity of hormones, cytokines, or growth factors, have also been
observed (Foretz et al., 2014; Vella et al., 2016; Zhu et al., 2016).
Thus, different, and apparently unrelated mechanisms of action,
have been identified in different tumor cells as responsible of
metformin antiproliferative activity. However, the observation
that, at least in vitro, structurally-related biguanides are endowed
with similar antitumor activity raises the possibility that a “class-
effect” could be at the basis of such an activity. If this is
the case, all the different effects on intracellular transduction
systems triggered by metformin in different tumor cells might
be dependent on a master molecular mechanism shared by
all biguanides, granting these molecules a selective functional
toxicity toward cancer cells while sparing normal cells. Following
this idea, we recently identified a novel transduction mechanism
specifically responsible for the proliferation of human GSCs and
involved in metformin antitumor activity: the inhibition of the
chloride intracellular channel 1 (CLIC1) activity (Gritti et al.,
2014). CLIC1 is a metamorphic protein mainly localized in the
cytosol as inactive monomer that under stress conditions, and
in particular during the G1/S phase transition of the cell cycle,
translocates to the membrane where it induces chloride ion
influx to trigger proliferation (Peretti et al., 2015). Importantly,
differently from normal cells where only few channels are active,
CLIC1 activity is increased in tumor cells, suggesting that CLIC1
could represent a tumor-specific drug target (Setti et al., 2013).
We reported that metformin binds CLIC1 in the extracellular
portion of the putative pore region, thus blocking chloride
current and causing cell proliferation arrest (Gritti et al., 2014).
As expected from the tumor selective CLIC1 activity, metformin
effects on chloride influx and cell division occurred only in
GSCs, but not in human umbilical cord mesenchymal stem cells
(ucMSC) (Gritti et al., 2014).
On these premises, numerous clinical trials were started to
test the antitumor activity of metformin in different human
tumors, and several are still ongoing (Heckman-Stoddard et al.,
2017). However, important issues and concerns about this off-
label activity are still unsolved. In particular, extremely high drug
concentrations (within the mM range) are required to induce
antitumor effects in in vitro studies, although in vivo metformin
intratumoral concentrations were reported to be several fold
higher than in plasma (Nguyen et al., 2017; Baldassari et al., 2018).
It was therefore proposed that protracted in vivo treatment using
clinically reachable doses, can possibly induce antitumor effects
(Gritti et al., 2014). Notwithstanding, novel derivatives, retaining
the same efficacy and safety profile of metformin, but endowed
with higher potency, are currently intensively searched.
In this study, we compared efficacy and potency as far
as antitumor activity in human GSCs of known biguanides
approved for different diseases. In particular, we tested
phenformin, a withdrawn antidiabetic drug, moroxydine, a
former antiviral agent, and the antimalarial agent proguanil,
all showing a biguanide linear structure as in metformin, and
cycloguanil, the active form of proguanil, which contains a
cyclized biguanide moiety. Moreover, we tested the activity
of phenformin, moroxydine, proguanil, and cycloguanil
on CLIC1 activity to establish whether its inhibition may
represent a biguanides’ pharmacological class effect. This is
of particular relevance to pave the way to the development of
therapeutically improved novel compounds acting through the
same mechanism of action but showing better pharmacokinetic
and pharmacodynamic characteristics in comparison to known
biguanides.
MATERIALS AND METHODS
Reagents and Antibodies
Metformin (1,1-dimethylbiguanide hydrochloride), phenformin
[1-(2-phenylethyl)-biguanide hydrochloride], dissolved in water,
and IAA94 (indanyloxyacetic acid 94), in ethanol, were
from Sigma-Aldrich (Milan, Italy). Moroxydine, cycloguanil
and proguanil, were synthesized according to the procedures
previously reported (Curd and Rose, 1946; Modest, 1956; Shapiro
et al., 1959) and stock solutions were prepared in DMSO. The
correspondent amount of DMSO (for moroxydine, cycloguanil
and proguanil, max 0.3%) or ethanol (for IAA94, max 0.2%)
was added in the control points, although we observed that,
at these concentrations, the vehicles did not modify any of the
parameter tested. Growth factor-reduced MatrigelTM was from
BD Biosciences (Franklin Lakes, NJ, United States), type 1 rat
tail collagen from SERVA Electrophoresis GmbH (Heidelberg,
Germany), and methylcellulose from Sigma-Aldrich.
The following antibodies were used: anti-CLIC1 cl. F9 and cl.
356.1 (Santa Cruz Biotechnology, Dallas, TX, United States) for
immunofluorescence and Western blot experiments, respectively;
anti-GFAP, anti-nestin, anti-Oct4, anti-Sox2, and anti-MAP-2
(Abcam, Cambridge, United Kingdom); anti-Olig2 and anti-
Sox2, (Merck Vimodrone, Italy); anti-mouse and anti-rabbit
Alexa Fluor 488 and 568 secondary antibodies (Thermo Fisher
Scientific, Carlsbad, CA, United States).
Human GSC and ucMSC Cultures
Human GSCs
Cultures were obtained from post-surgical samples of GBM grade
IV (WHO classification) derived from 7 patients (3 females
and 4 males, age range: 40–73, average 62 years old) and
coded as GBM1 to GBM7. Post-surgical samples were used after
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patients’ informed and written consent and Institutional Ethical
Committee (IEC) approval. All patients underwent surgery at
Neurosurgery Department (Ospedale Policlinico San Martino,
Genova, Italy) and had not received therapy prior to the
intervention. Detailed information on individual patients is
reported in Table 1.
Glioblastoma stem cells, isolated as described (Gatti et al.,
2013), were grown in stem cell-permissive medium enriched
with 10 ng/ml human bFGF and 20 ng/ml human EGF
(Miltenyi Biotec, Bergisch Gladbach, Germany) (Bajetto et al.,
2013). Sphere formation occurred within 2 weeks of culture
(Figure 1). For survival and electrophysiology experiments, GSCs
were grown as monolayer on growth factor-reduced Matrigel
coating, allowing easier evaluation without affecting stem cell
features (Griffero et al., 2009). Validation of GSC properties
of the cultures (i.e., self-renewal capacity, stem cell marker
expression, multipotency, and tumorigenicity) was performed
as described (Wurth et al., 2013) (Figure 1). All the cultures
analyzed in this study have been characterized in previous works
for tumor-initiating capacity by orthotopic injection of 10,000
sphere-derived cells in 6–8 weeks old non-obese diabetic severe
combined immunodeficient (NOD/SCID) mice (Charles River
Laboratories, Wilmington, MA, United States) (Carra et al., 2013;
Wurth et al., 2013; Gritti et al., 2014; Corsaro et al., 2016). Cell
differentiation was carried out by shifting GSC cultures in serum-
containing medium (10% FBS) for at least 15 days (Griffero et al.,
2009; Gatti et al., 2013).
Genetic alteration analysis in GSCs was performed by
multiplex ligation-dependent probe amplification (MLPA)
analysis. Briefly, genomic DNA was isolated from GSCs and
normal human astrocytes (ScienCell Research Laboratories,
Carlsbad, CA, United States) using QIAamp DNA microkit
(Qiagen). The MLPA analysis (SALSA MLPA KITs P175-
A1 Tumor-Gain and P294-A1 Tumor-loss, MRC Holland,
Amsterdam, Netherlands) was performed using 100ng of
genomic DNA, following the manufacturer’s instructions. The
resulting DNA fragments were identified and quantified by using
capillary electrophoresis on an ABI XL3130 genetic analyzer
(Applied Biosystems, Foster City, CA, United States) and the
Genemapper program (version 4.0 – Applied Biosystems). Data
were analyzed with the Coffalyser software (MRC-Holland). For
each GBM, gains and losses were assigned by comparing the
peaks between the patient and the reference samples (DNA from
normal human astrocytes), as previously described (Monticone
et al., 2012, 2014).
CLIC1 gene down-regulation: short hairpins mRNA specific
for human CLIC1 (5′-GATGATGAGGAGATCGAGCTC-3′)
and firefly luciferase (5′-CGTACGCGGAATACTTCGA-3′) were
cloned into the XhoI/HpaI sites of the pLentiLox 3.7 lentiviral
vector and stably expressed in GBM2 CSCs, as reported (Setti
et al., 2013; Gritti et al., 2014). CLIC1 downregulation was
evaluated by Western blot (to monitor protein content) and by
electrophysiology (to monitor channel activity).
Human ucMSCs
Cells were isolated from umbilical cords, obtained after
cesarean section at Obstetrics and Gynecology Department
of International Evangelical Hospital (Genova, Italy) following
informed consent and approval by IEC, as reported (Bajetto
et al., 2017). Briefly, after vessel removal, cords were treated
with collagenase (0.5 µg/ml) to expose Wharton jelly and
obtain single cells. Cells, grown in MesenPRO RS MediumTM
(Gibco, Thermo Fisher Scientific), underwent flow cytometry
phenotypical characterization (MSC Phenotyping Kit, Miltenyi
Biotec), showing that more than 95% of the cells, in each
independent culture, were negative for hematopoietic antigens
(CD45, CD34, CD14) and MHC class-II, but expressed
CD73, CD105, CD90, CD29, and MHC class-I. Multipotency
was demonstrated showing that after incubation in selective
media, ucMSCs differentiate into osteocytic, chondrocytic, and
adipocytic lineages (Bajetto et al., 2017).
Immunofluorescence
Glioblastoma stem cells and differentiated GBM cells were fixed
with 4% paraformaldehyde, permeabilized with PBS/0.1% Triton
X-100, blocked with normal goat serum and immunostained
with the appropriate antibody, followed by fluorochrome-
conjugated secondary antibody (Wurth et al., 2017). Nuclei
were counterstained with DAPI (Sigma-Aldrich). Slides were
photographed with a DM2500 microscope (Leica, Milan,
Italy) equipped with a DFC350FX digital camera (Leica) or
confocal microscope (Bio-Rad MRC 1024 ES) (Corsaro et al.,
2016).
Western Blot Analysis
Cells were lysed in RIPA buffer and processed as reported (Florio
et al., 2001). Proteins (20 µg), transferred to PVDF membrane
(Bio-Rad Laboratories) and probed with primary antibodies,
were then incubated with appropriated secondary antibodies
and immunocomplexes detected by Clarity and Western ECL
Substrates (Bio-Rad Laboratories).
Cell Proliferation and Survival Assays
MTT Assay
Mitochondrial function, as index of cell viability, was evaluated
by measuring the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma-Aldrich), as reported
(Porcile et al., 2014). Briefly, 4000 GSCs, differentiated GBM
cells, or ucMSCs were treated with vehicle or the tested
drugs for 48 h in dose-response experiments; afterwards,
cells were incubated with 0.25 mg/ml MTT in serum-free
medium for 2 h at 37◦C; after the removal of the medium,
formazan crystals were dissolved in DMSO and absorbance was
spectrophotometrically measured at 570 nm, using an ELx800
microplate reader (BioTek, Winooski, VT, United States) (Villa
et al., 2016a).
Cell Counting
Glioblastoma stem cells from different tumors, grown in
standard conditions for 3 days in the presence or absence
of vehicle or biguanides, were counted with an automated
cell counter (TC20, Bio-Rad Laboratories, Inc., Hercules,
CA, United States) every 24 h. Briefly, after treatments,
cells were harvested and the suspension was diluted 1:10
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FIGURE 1 | Characterization of human glioblastoma stem cells. Representative images of GSC (derived from GBM6) spheroids (A) and monolayer on Matrigel (B)
cultured in stem cell medium supplemented with EGF and bFGF and differentiated cells (C) obtained by switching culture conditions from growth factor-deprived to
FBS-containing medium. Left panels reproduce phase contrast images at different magnification (10× and 20×). Right panels depict immunofluorescence for stem
cell markers OLIG2, nestin, and Oct4 (A,B), and the glia (GFAP) and neuron (MAP-2) differentiation markers (C). GFAP and MAP-2 expression is depicted from the
same microscope field, showing in most cells the co-expression of both markers. Similar results were obtained analyzing all the GSC cultures that enter the study.
in sterile PBS and mixed with an equal volume of 0.4%
Trypan Blue solution. Cell viability was calculated as % of
viable cells divided by the total number of cells (Villa et al.,
2016b).
Apoptosis Detection
Cells were treated with vehicle or the different biguanides at
concentration corresponding to the respective IC50, and stained
with Annexin V-FITC and propidium iodide (PI) (Apoptosis
Detection kit; Thermo Fisher Scientific). Samples were analyzed
by FACScalibur (BD Biosciences), equipped with BD CellQuest
Pro software. The percentage of cell death was obtained
by summing-up the percentages of early and late apoptosis
(Pattarozzi et al., 2017).
Evaluation of GSC Invasiveness
Chemoinvasion Assay
Experiments were performed in a 48-well modified Boyden
chamber using 8 µm nuclepore polyvinylpyrrolidine-free
polycarbonate filters, coated with Matrigel (100 µl/filter).
Boyden chamber was assembled with the coated side of the filter
facing the cells in the upper compartment. GSCs were suspended
at a density of 1 × 106 cells/ml in DMEM/F12 containing 0.1%
bovine serum albumin, and 50 µl/well of the cell suspension
were added to the upper chamber after 10 min pre-treatment
with drugs or the corresponding vehicles. Drugs were present
throughout the experiments. DMEM/F12 medium supplemented
with 10% FBS was used as attractant in the lower chamber. After
6 h of incubation at 37◦C, non-migrated cells on the upper
surface of the filter were removed by scraping. The cells that had
migrated to the lower side were stained with Diff-Quick stain
(WVR, Radnor, PA, United States), and 5–8 unit fields per filter
were counted by a scorer, blind to the experimental conditions,
with a Zeiss microscope.
Three-Dimensional (3-D) Invasion Assay
Multicellular tumor spheroids were generated in the presence of
methylcellulose as previously described (Cattaneo et al., 2012),
with minor modifications. Briefly, GSCs were suspended at a
density of 25,000 cells/ml in DMEM/F12 containing 1% FBS
and 3% methylcellulose, 200 µl/well of the cell suspension
were seeded in non-adherent round bottom 96-well plates and
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centrifuged for 10 min at 400 × g immediately after plating.
Tumor spheroids were harvested within 24 h, suspended in
DMEM/F12 containing 10% FBS and 0.9% methylcellulose,
and mixed with an equal volume of a collagen stock solution
prepared by mixing at 4◦C acidic rat tail collagen (2 mg/ml;
8 vol) with 1 vol of 10× DMEM and 0.1 M NaOH, to
adjust pH to 7.4. Drugs, or the corresponding vehicles, were
added to suspended spheroids before embedding them into
collagen. Spheroid-containing gel was rapidly transferred into
pre-warmed 24-well plates, and incubated for 24 h at 37◦C in
5% CO2. In-gel invasion was quantified by measuring the length
of all of the processes originating from individual spheroids
using the ImageJ software (United States National Institutes of
Health, Bethesda, MA, United States). At least 10 randomly
selected spheroids per experimental group were measured in each
experiment.
Sphere-Formation Assay
Glioblastoma stem cells were seeded in complete medium in the
absence of Matrigel in 48-well plates at 1000 cells/well. After
24 h, cells were exposed to different concentration of biguanides
according to the calculated IC50, and monitored for 5 days,
to allow sphere generation. The number of spheres/well was
quantified using a digital camera mounted on a transmitted
light microscope to image each individual well, and visually
calculated by three independent operators, as reported (Angeletti
et al., 2016). To further demonstrate the inhibitory activity of
biguanides on sphere-formation process, GBM-derived tumor-
spheres, generated in the absence or presence of biguanides, were
disaggregated into single cells and re-plated at 1000 cells/well in
fresh medium. Spheres-formation capacity was re-evaluated after
5 days, (on day 10, secondary spheres) and further repeated to on
day 15 (tertiary spheres).
Electrophysiology
Patch electrodes (GB150F-8P with filament, Science Products)
were pulled from hard borosilicate glass on a Brown-Flaming
P-87 puller (Sutter Instruments, Novato, CA, United States)
and fire-polished to a tip diameter of 1–1.5 µm and an
electrical resistance of 5–7 M. Patch-clamp electrophysiology
was performed in perforated-patch whole cell configurations, as
reported (Gritti et al., 2014).
The voltage protocol consisted of 800 ms pulses from−40 mV
to +60 mV every 10 s. Current amplitude was measured as trace
average between 700 and 750 ms. Patch clamp solutions were the
following: bath solution (mM): 140 NaCl, 5 KCl, 10 HEPES, 1
MgCl2, 2 CaCl2, 5 D-Glucose, pH 7.4. Pipette solution (mM): 135
KCl, 10 HEPES, 10 NaCl, 1 MgCl2, 2 CaCl2, 5 D-Glucose, pH 7.4.
CLIC1 Current Detection
Chloride intracellular channel 1 activity was detected using
electrophysiological measurements. Cells under continuous
membrane current monitoring were constantly perfused with
external solution at 1 ml/min. Once current recordings reached
a constant value, cells were challenged with the different
biguanides, followed by addition of IAA94 (100 µM) to get
maximum inhibition (Tonini et al., 2000). Data reported in
the box chart plots are the current ratio between the effect of
each biguanide at the reported concentrations, and the residual
IAA94-sensitive current.
Statistical Analysis
All data are presented as means ± SEM. Statistical significance
was established at p-value ≤ 0.05. Prism version 5.02 (GraphPad,
San Diego, CA, United States) software was used to analyze the
results. All experiments were repeated independently at least
three times (n) each performed in triplicate or quadruplicate
(as indicated). The half maximal inhibitory concentration
IC50 was calculated using non-linear regression curve fit
analysis selecting the log(drug) vs. response-variable slope
(four parameters) equation Statistical significance between two
independent groups was assessed by t-test (unpaired, two-
tailed) or one-way ANOVA for multiple groups, followed by
Tukey’s, Dunnett’s or Bonferroni’s post hoc tests (post hoc
tests were only applied when ANOVA gave p < 0.05). Direct
comparison between GSCs and differentiated GBM cells after
biguanides treatment were performed using two-way ANOVA
with interaction terms between cell type and concentration; this
analysis was followed by post hoc Bonferroni test to determine
at which concentration the effect of treatment was statistically
significant.
RESULTS
GSC Isolation, Culture, and
Differentiation
Glioblastoma stem cells were isolated from seven human GBMs
(see Table 1 for patient and tumor characteristics). As expected,
GBM analyzed were heterogeneous with 3 classified as neural
(GBM1, 2, and 4) and 1 as “mesenchymal” (GBM 3) and
only GBM2 showed unmethylated MGMT promoter. Similar
to normal stem cells, isolated GSCs, cultured in chemically
defined medium (without serum and containing EGF and bFGF),
are able to grow in vitro as spheroids or loosely adherent
clones expressing stem cell-related markers (i.e., OLIG2, nestin)
(Figure 1A). Alternatively, to perform a better analysis of GSC
pharmacological responses, cells were cultured on Matrigel in
the same medium (Griffero et al., 2009; Gritti et al., 2014) thus
allowing the proliferation as monolayer. Importantly, in both
culture conditions, GSCs are able to self-renew, to retain stemness
marker expression (i.e., OLIG2 and Oct4) (Figure 1B) and the
tumorigenic ability [as we reported in previous studies (Carra
et al., 2013; Wurth et al., 2013; Gritti et al., 2014; Corsaro et al.,
2016)]. From a molecular point of view, loss of CDKN2a was
detected in GSCs from GBM1, 2, 3, and 5, PTEN in GBM1, 2 and
3, TP53 only in GBM1; moreover, gain of EGFR was observed in
GBM1 and 2, and of BRAF in GBM1, 2, and 5 (for more details
see Table 1).
Glioblastoma stem cell cultures, shifted for 15 days in
serum-containing medium, undergo astrocytic and/or neural
differentiation (i.e., increased expression of GFAP and MAP-2,
Figure 1C) representing an in vitro model of the bulk of
heterogeneous non-stem cells in GBM mass.
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Biguanides Inhibit GSC Proliferation With
Different Potency
We tested the effects of phenformin, cycloguanil, moroxydine,
and proguanil on GSC viability in comparison with metformin.
The molecular structures of the biguanides analyzed are reported
in Figure 2A. In particular, we performed concentration-
response experiments to determine both potency and efficacy of
the different molecules. Growth inhibitory activity, measured by
MTT assay after 48 h of treatment, was evaluated on GSCs grown
on Matrigel. Indeed, we previously reported that metformin
retains antiproliferative effects on GSCs, when grown either as
spheroids or as monolayers (Wurth et al., 2013). The analysis
was performed in seven individual GSC cultures (GBM1-7) to
cope with GBM heterogeneity. Concentration-response curves,
derived from the average results from all the culture tested,
are reported in Figure 2B (curves of the effects of drugs on
individual GBMs are reported in Supplementary Figure S1). In
agreement with previous results, metformin caused a significant
inhibition of GSC viability in all seven GBMs with a maximal
inhibition of about 84% at 30 mM, and an average IC50 value
of 9.4 mM (range: 2.1–12.9 mM) (Figure 2B and Table 2).
Similar inhibitory effects were obtained with phenformin and
cycloguanil on GBM1-6, and moroxydine on GBM1-4 and
6. However, phenformin, cycloguanil and moroxydine showed
potencies more than 10-fold higher than metformin (0.35, 0.18,
and 0.53 mM, respectively) (Figure 2B and Table 2). As far
as efficacy, phenformin and cycloguanil showed a maximal
inhibition of cell viability comparable to that of metformin
(−96 and −81%, respectively, at 3 mM concentration), while
moroxydine was less effective (−63%) (Figure 2B and Table 2).
On the other hand, proguanil induced cytotoxicity with a low
concentration-dependency, causing modest effects till 30µM and
an almost complete cell death at the concentration of 100 µM.
Although the calculated IC50 was very low (54 µM), this curve
is reminiscent of a non-specific cytotoxic effect (Figure 2B and
Table 2).
Similar results were obtained measuring cell viability by
Trypan blue exclusion test after treatment of GBM 2 and 4 CSCs
for 48 h with the different molecules (Figure 3). The drugs
were used at concentrations around the previously identified IC50
values. Also in these experiments cycloguanil confirmed to be
the most potent and efficacious biguanide in contrasting GSC
proliferation (Figure 3C).
Next, we tested whether the antiproliferative effects of these
biguanides could be ascribed to the activation of the apoptotic
program by measuring annexin-V binding after 24 or 48 h of
GBM2 and GBM4 CSC treatment. Metformin (10 mM) did not
show pro-apoptotic activity after both 24 h (data not shown)
and 48 h (Figure 4) of treatment. Similar results were also
obtained using GBM3 cells (data not shown). A slight induction
of apoptosis was observed in GBM2 and GBM4 CSCs after
24 h treatment with phenformin, cycloguanil, and moroxydine,
although did not reach statistical significance (data not shown).
Conversely, 48 h of treatment of GBM2 caused an increase of+15
(p < 0.05), +12.5 (p < 0.05), and +8% (n.s.) with phenformin,
cycloguanil, and moroxydine, respectively (Figure 4), while
a statistical significant increase in annexin-V positivity was
measured in GBM4 CSCs treated with all the drugs (about
+20% over control cells, reaching a significance of p < 0.05)
(Figure 4). The specificity of the effects of the tested drugs against
GSC subpopulation was further demonstrated showing that
24 h treatment of GBM1 and GBM2 cultures with metformin,
phenformin, cycloguanil, and moroxydine significantly reduced
the expression of Sox2 (Supplementary Figure S2), a specific
GSC marker, which is down-regulated in differentiated GBM cells
(Banelli et al., 2015).
Biguanides Inhibit GSC Invasiveness
Invasion of surrounding brain parenchyma is one of the main
obstacle to the effective treatment of GBM. In chemoinvasion
tests, we show that both GBM2 and GBM4 CSCs efficiently
move through Matrigel (Figure 5A) and sprout out of spheroids
in 3-D invasion assays (Figure 5D). We therefore tested
the effect of metformin (10 mM), phenformin (0.5 mM),
cycloguanil (0.1 mM), and moroxydine (1 mM) on the in vitro
invasive properties of GBM2 and GBM4 cells. GSC invasion
through Matrigel was significantly reduced by all the drugs
(Figures 5B,C). No significant differences among metformin and
the other biguanides were observed as far as the efficacy of
the anti-invasive effects, ranging from about −50% to −30% of
invading cells, in GBM2 and GBM4, respectively. However, the
anti-invasive effects occurred at quite higher concentrations for
metformin as compared to the other drugs, (Figures 5B,C), as
already observed in cell viability assays.
Glioblastoma stem cell invasiveness was also tested in
a 3-D assay on multicellular spheroids which more closely
reproduce tissue-like morphology and cell-to-cell interactions.
In these experimental conditions, phenformin, cycloguanil, and
moroxydine significantly reduced the sprouting area of both
GBM2 and GBM4 CSCs (about −60 and −50%, respectively)
(Figures 5E,G and Supplementary Figure S3 for representative
images of GSCs sprouting out from spheroids). At variance,
metformin efficiently reduced 3-D sprouting only in GBM4
(about −40%, Figures 5G,H) whereas it was much less effective
in GBM2 cells, did not reaching statistical significance (−20% of
control cells, Figures 5E,F).
Biguanides Inhibit GSC Spherogenesis
Biguanide-induced changes of spherogenesis activity, a surrogate
in vitro index of the self-renewal ability of GSCs (Soeda et al.,
2008), were evaluated in four cultures (GBM1, 2, 4, and 5) to
demonstrate the specific efficacy of the different drugs on GSCs.
First we show that the GSC cultures used were able to self-renew.
To do this, we allowed 1000 cells to form spheres for 5 days;
these spheres were disaggregated and sequentially 1000 cells
replated every 5 days. In untreated cells we observed an unaltered
spherogenesis activity over the time (Figure 6A). The effects of
metformin, phenformin, cycloguanil, and moroxydine (used at
IC50-related concentrations) on self-renewal was tested treating
1000 cells at the moment of the first plating and evaluating
after 5 days the number of spheres generated; the spheres were
then disaggregated and 1000 cells replated in medium without
drugs, and the formation of secondary spheres was measured
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FIGURE 2 | Metformin, phenformin, cycloguanil, moroxydine, and proguanil affect viability of glioblastoma stem cells. (A) Structural formulas of the compounds
tested with the biguanide moiety highlighted in red. (B) Dose-response curves of the antiproliferative effect of biguanide derivatives on GBM CSC viability, evaluated
by MTT assay after 48 h of treatment. Data were obtained from several GSC cultures, and represent the mean ± SEM of at least n = 3 independent experiments for
each GBM, performed in quadruplicate on each culture. Metformin effects were tested in all the 7 GSC cultures, phenformin and cycloguanil in GBM1-6, moroxydine
in GBM1-4 and 6, and proguanil in GBM2-4. Effects on individual GBM cultures are reported in Supplementary Figure S1. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001
vs. CTR (ANOVA, Dunnett’s post hoc test).
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TABLE 2 | IC50 and efficacy values of the antiproliferative activity of different biguanides on GSC cultures isolated from individual human GBMs.
GSC code Compound (mean IC50, mM)
Metformin Phenformin Cycloguanil Moroxydine Proguanil
GBM1 12.96 0.19 0.16 0.53 n.d.
GBM2 12.30 0.29 0.22 0.47 0.043
GBM3 6.22 0.60 0.15 0.54 0.034
GBM4 12.65 0.37 0.21 0.57 0.087
GBM5 2.10 0.20 0.21 n.d. n.d.
GBM6 9.12 0.46 0.81 0.59 n.d.
GBM7 6.65 n.d. n.d. n.d n.d.
Average IC50 (mM ± SEM) 9.41 ± 1.54 0.35 ± 0.06 0.18 ± 0.10 0.53 ± 0.02 0.054 ± 0.016
Efficacy 84% 96% 81% 50% 98%
(% max cell death)[mM] [30 mM] [3 mM] [3 mM] [3 mM] [1 mM]
ucMSC (mean IC50 mM ± SEM) n.r n.r. n.r. n.r. 0.048 ± 0.003
IC50 values and the average efficacy (i.e., maximal inhibition of cell viability) of each compound is reported, as well as the effects on ucMSC viability.
n.d., not determined; n.r., not reached.
FIGURE 3 | Metformin, phenformin, cycloguanil, and moroxydine exert antiproliferative activity on glioblastoma stem cells. Inhibition of GSC proliferation by
metformin (A), phenformin (B), cycloguanil (C), and moroxydine (D) was evaluated by counting number of cells after 48 h of treatment with various concentrations
derived from the IC50 values, as calculated in Table 2. Experiments were performed on both GBM2 and GBM4 cultures, and data represent the average ± SEM of
n = 3 independent experiments performed in quadruplicate. ∗p < 0.05, ∗∗∗p < 0.001 vs. respective CTR (ANOVA, Dunnett’s post hoc test).
in the following 5 days, this procedure was repeated for a third
passage to test the ability of tertiary sphere formation capability
of GSCs. In these experiments, although with different efficacy
and with tumor-specific activity all the tested drugs were able
to significantly reduce the number of cells able to generate new
spheres (Figures 6B,C). In line with the previous experiments,
moroxydine showed the lowest efficacy also on the inhibition
of GSC self-renewal. Moreover, the different GBMs showed
distinct sensitivity, with GBM1 being the more responsive (no
spheres were generated after metformin treatment already after
the first sphere formation assay on day 5, while phenformin
and cycloguanil abolished spherogenesis after 10 days, and
moroxydine after 15 days); conversely, GBM2 was the least
sensitive since although reduced in number, few spheres were
generated even at 15 days after metformin, phenformin and
moroxydine treatment.
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FIGURE 4 | Pro-apoptotic effects of metformin, phenformin, cycloguanil, and moroxydine on glioblastoma stem cells. Induction of apoptosis by biguanide treatment
for 48 h was detected by annexin V binding, measured by FACS in GBM2 (left) and GBM4 (right) CSCs. Metformin did not significantly increase apoptosis neither
in GBM2 nor in GBM4. Phenformin and cycloguanil increased apoptotic cell number in both GBM2 and GBM4 CSCs, while moroxydine significantly affected only
GBM4 CSCs. Bars represent the percentage of annexin V-positive cells ± SEM, counting 10,000 events per experimental points. Experiments were repeated twice
using independent cell preparations. ∗p < 0.05, vs. CTR (t-test).
Inhibition of CLIC1 Activity as Common
Mechanism of the Antiproliferative
Activity of Biguanides
We previously reported the role of CLIC1 membrane activity as
selective and pivotal regulator of GSC proliferation. In agreement
with these data, we confirmed that CLIC1 is enriched in GBM
stem-like cells. In fact, CLIC1 was detected in spheroid cells
derived from GBM2 and GBM4 which also co-express the neural
stem cell marker OLIG2 (Figure 7A). Similar results, although
showing different level of expression, were also obtained by
Western blot analysis, in representative cultures, in Figure 7B.
Moreover, the treatment of five GSC cultures with IAA94
(100 µM), a selective CLIC1 inhibitor (Valenzuela et al., 2000),
reduced cell viability in all the cultures, as measured by MTT
assay (Figure 7C). Conversely, IAA94 was ineffective in the
correspondent differentiated cells from three of these GBM
cultures and in three independent normal ucMSC cultures
(Figure 7C), in line with the previous observations that in
these cell types CLIC1 is dispensable for cell proliferation (Gritti
et al., 2014). Finally, measuring annexin V binding by FACS,
we observe that IAA94 (100 µM) treatment caused a low level
of apoptosis in GBM4 (but not in GBM2) CSCs after 48h
(Figure 7D), as we observed with the biguanide derivatives (see
Figure 4). Finally, CLIC1 inhibition induced by IAA94 (100 µM)
treatment significantly reduced the ability of GBM1, GBM2, and
GBM4 to self-renew (Figure 7E), as assessed in a spherogenesis
assay and detailed in the previous paragraph.
Thus we checked whether the antiproliferative activity of
the tested biguanides was dependent on a direct inhibition
of CLIC1-associated membrane chloride current, as observed
using metformin (Gritti et al., 2014). To test the activity
and the relative potency of the different drugs, patch-clamp
voltage-clamp experiments were performed in both GBM2
(Figure 8) and GBM4 CSCs (Supplementary Figure S3). Cells
from each of these cultures were challenged in current time-
course experiments in the presence of the biguanides at two
different concentrations referred to the IC50 values determined
in cell viability experiments. Data are reported as time-dependent
current values during the sequential perfusion with vehicle
(control), biguanides and IAA94. A correspondent box chart
plots reports the percentage of inhibition induced by biguanides
as ratio of the current block operated by IAA94, used at a
concentration (100 µM) that completely inhibits CLIC1 activity
(Tonini et al., 2000; Valenzuela et al., 2000) and represents
CLIC1 current not affected by the tested drugs. Metformin
caused a powerful inhibition of CLIC1 current (i.e., a very small
reduction of residual membrane current was induced after adding
IAA94 in metformin-treated cells). Similarly, also phenformin,
cycloguanil and moroxydine inhibited CLIC1-associated ion
current, in a concentration dependent manner. However, the
potency differences observed in the viability assays (see Table 2)
were confirmed in electrophysiology experiments: a maximal
inhibition of CLIC1 activity was obtained with metformin
at the concentration of 10 mM, with 1 mM phenformin,
0.5 mM cycloguanil, and 1 mM moroxydine (Figure 8 and
Supplementary Figure S4). Moreover, since phenformin did
not cause a complete inhibition of the current (as shown by
the additive inhibitory effect induced by IAA94 in the presence
of the biguanides), we propose that this molecule might exert
antiproliferative effects also via CLIC1-independent pathways.
Moroxydine showed an incomplete CLIC1 inhibition but also
a lower reduction of GSC viability, indicating a low efficacy
as CLIC1 inhibitor and as antiproliferative agent for GSCs,
but confirming the relationship between CLIC1 inhibition and
antiproliferative effects. Because cycloguanil caused a complete
inhibition of CLIC1 current at concentrations correspondent to
the antiproliferative IC50, it is evident that it is the most selective
CLIC1 current inhibitor among all the tested compounds. The
relevance of this mechanisms in the antiproliferative activity
of the tested biguanides was further shown evaluating their
antiproliferative activity in GBM2 CSCs (siCLIC1 cells) in which
CLIC1 expression was down-regulated (−60% of both protein
levels and channel activity, Supplementary Figures 5A,B). It
was not possible to completely abolish CLIC1 gene expression
since, in these conditions, cells are not viable. As compared
to cells transfected with the empty vector (siLuc cells), in
siCLIC1 cells the efficacy of all the drugs was significantly
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FIGURE 5 | Biguanides inhibit glioblastoma stem cells invasiveness. (A) Basal GSC invasiveness was tested by measuring the number of invading GBM2 and GBM4
cells in chemo-invasion assays. Invading GBM2 (B) and GBM4 (C) cells were quantified in the absence (CTR) or in the presence of metformin (met, 10 mM),
phenformin (phen, 500 µM), cycloguanil (CG, 100 µM) or moroxydine (mor, 1 mM). Data are expressed as the percent of the number of invading control cells (CTR)
set at 100%. ∗∗p < 0.01, ∗∗∗p < 0.001 vs. CTR, n = 3. One-way ANOVA followed by Bonferroni’s post hoc test. (D) Cumulative length of invading sprouts emerging
from spheroids obtained from GBM2 or GBM4 cells were quantified after 24 h of incubation as described in the “Materials and Methods” section. Cumulative length
of invading sprouts emerging from GBM2 (E) and GBM4 (G) spheroids were quantified after 24 h of incubation in the absence (CTR) or in the presence of metformin
(met, 10 mM), phenformin (phen, 500 µM), cycloguanil (CG, 100 µM), or moroxydine (mor, 1 mM). Data are expressed as the percent of the cumulative sprouting
measured in control spheroids (CTR) set as 100%. ∗∗∗p < 0.001 vs. CTR, n = 3. One-way ANOVA followed by Bonferroni’s post hoc test. Representative images of
GSCs sprouting outside the spheroids from control or metformin-treated GBM2 and GBM4 CSCs are shown in (F,H), respectively, while representative images
following the treatment with the other biguanides are reported in the Supplementary Figure S2.
reduced (Supplementary Figure 5C). However, we do not
have a complete abolishment of the antiproliferative activity
of the drugs, especially with the drugs more effective in the
inhibition of CLIC1 such as metformin, since the inhibition of
the residual activity of the channel still causes a reduction of CSC
proliferation.
Importantly, proguanil (50 and 100 µM, Figure 8) did
not affect CLIC1 activity, clearly indicating that the high
level of cytotoxicity observed in the previous experiments was
independent from the blockade of CLIC1-mediated membrane
chloride current, the molecular target of the other biguanides,
and it is likely attributable to an in vitro non-specific effect.
On the other hand, we confirmed that the effects of the
biguanides on CLIC1 activity was merely functional since we did
not observe changes in the channel expression after treatment
with metformin, phenformin, cycloguanil, moroxydine, and
IAA94, used as control compound (Supplementary Figure S6).
Specificity of CLIC1 Inhibition in the
Antiproliferative Activity of Biguanides
To test whether the antiproliferative activity of biguanides is
specifically mediated by targeting CLIC1 activity, we measured
the effects of the different biguanides on the viability of cells
in which it was previously demonstrated that CLIC1 activity
is not necessary for cell cycle progression (Wurth et al., 2013;
Gritti et al., 2014). In particular, we tested the biguanides on
the proliferation of differentiated GBM cells (obtained from
the same GSC cultures previously analyzed by shifting cells
in FBS-containing medium, see Figure 1), and ucMSCs. In
both cell types we previously reported low levels of CLIC1-
dependent ion current (Gritti et al., 2014). In fact, IAA94,
used at 100 µM, a concentration that completely blocks
CLIC1 activity (Tonini et al., 2000), did not affect viability
of both differentiated GBM cells or ucMSCs (see Figure 7B).
In agreement with previous data (Wurth et al., 2013; Gritti
et al., 2014), metformin marginally affects differentiated GBM
cell viability (−20% vs. controls) only when used at extremely
high concentrations (i.e., 50 mM, Figure 9A and Supplementary
Table S1 for statistical significance). Conversely, phenformin
caused a significant reduction of cell viability starting from
concentrations around the IC50 value (0.3 mM), and the
toxic effect further increased in a concentration-dependent
manner reaching a maximal effect at 3 mM (Figure 9A and
Supplementary Table S1). Cycloguanil did not show toxic effects
on differentiated GBM cells for concentrations up to the IC50
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FIGURE 6 | Biguanide treatment impairs sphere formation in glioblastoma stem cells. (A) GSC cultures possess self-renewal capability. Sphere formation assay was
performed on four GSC cultures (GBM1, GBM2, GBM4, and GBM5); images of spheres were captured and counted as described in Section “Materials and
Methods.” On day 5, primary spheres were dissociated into single cells and 1000 cells subjected to another round of sphere formation assay, counted on day 10
(secondary spheres) and re-plated for the third time to asses sphere formation on day 15 (tertiary spheres). Representative microphotographs (magnification 10×)
and histograms quantifying sphere formation from GBM5 cells, are reported. Sphere formation assays were performed on GBM1, GBM2, GBM4, and GBM5 GSCs,
and measurement of primary, secondary and tertiary sphere number was assessed on day 5, in control and cultures with metformin (MET, 10 mM), phenformin
(PHEN, 0.25 mM), cycloguanil (CG, 0.2 mM), and moroxydine (MOR, 1 mM). (B) Representative microphotographs (magnification 10×) of GBM5 treated with
metformin (10 mM) are reported. (C) Quantification of biguanide impairment of sphere formation in GBM1, GBM2, GBM4, and GBM5. Histogram depicts the
time-course of the percentage of spheres developed in treated cultures after 5 days of exposure as compared to controls (5 days); after sphere disaggregation, single
cells were grown in the absence of drugs, and the formation of secondary spheres was evaluated on day 10 and, following further sphere dissociation, on day 15.
identified for the antiproliferative activity (about 0.3 mM), but
induced a moderate level of cell death at 1 and 3 mM (−30
and −48% viability vs. control cells). Conversely, moroxydine
did not affect differentiated GBM cell at all concentrations
tested. Finally, proguanil caused a dose-dependent cell death
in differentiated GBM cells, starting at low concentrations
(−31% cell viability at 0.03 mM) reaching more than 85%
loss of viability at the highest concentration tested (3 mM,
Figure 9A and Supplementary Table S1). Comparing the activity
of metformin, phenformin, cycloguanil, and moroxydine in
GSCs and differentiated cells from the same tumor, we show
a statistically significant higher inhibition of the biguanides in
GBM2, 3 and 4 (p-values ranged from <0.0001 to <0.001 for the
effect of the drugs in the different cell types, see Supplementary
Figure S5) with the exception of phenformin and moroxydine in
GBM4, in which, however, although dose-response curves were
not statistically different a significant difference was observed
for the highest concentrations tested in the two cell populations
(Supplementary Figure S7).
The same approach was used to investigate biguanide toxicity
on ucMSCs (Figure 9B and Supplementary Table S1). Also in
this case metformin and moroxydine did not affect cell viability
at all the concentrations tested. Phenformin confirmed a dose-
dependent toxicity that started to be statistically significant at
the concentration of 0.3 mM, and cycloguanil was ineffective
at the IC50-related concentrations but caused ucMSC death
for concentrations about 10-fold higher than the IC50 value.
The cytotoxic effect of proguanil on ucMSC was similar to
that observed in GSC cultures showing an “all-or-nothing”
effect, with a significant cytotoxicity already evident at the
concentration of 0.1 mM (Figure 9B and Supplementary
Table S1).
DISCUSSION
Repositioning of metformin as antitumor drug represents
one of the hot topics in pharmacological oncology (Coyle
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FIGURE 7 | CLIC1 expression in glioblastoma spheroids and its role in cell viability, apoptosis, and self-renewal of glioblastoma stem cells. (A) CLIC1 expression was
analyzed in GBM4 (upper) and GBM6 (lower) spheroids by immunofluorescence experiments. High expression of CLIC1 was detected in both spheroids, also
showing a high level of co-localization with the stem cell marker OLIG2 (lower). (B) Representative Western blots showing the expression of CLIC1 in GSC cultures
derived from GBM1, 2, 3, and 5. Beta-actin was used as reference housekeeping gene. (C) Effect of the CLIC1 inhibitor IAA94 (100 µM) on the viability of GSCs and
their differentiated (DIFF) counterpart, and umbilical cord mesenchymal stem cells (ucMSC), measured by MTT assay. Only in GSCs, CLIC1 inhibition caused
reduction of cell viability. Data are the mean of n = 2 experiments performed in quadruplicate, on each culture derived from 5 GSC cultures (GBM2, 3, 4, 5, 6), 3
differentiated cultures (GBM2, 3, and 4), and 3 independent ucMSC cultures. Dotted line represents control level set at 100%. ∗∗p < 0.01 vs. CTR cells. (D) Effect of
IAA94 (100 µM) on the induction of apoptosis in GSCs from GBM2 and GBM4, measured by annexin V binding. A moderate pro-apoptotic effect (about 23%
annexin V-positive cells) was observed only after 48 h of treatment in selected cultures (i.e., GBM4), while other cultures (GBM2) were not affected. Data are
expressed as the mean of n = 3 independent experiments. ∗p < 0.05 vs. CTR (t-test). (E) Effect of IAA94 (100 µM) on GBM1, 2, and 4 spherogenesis. Cells were
treated for 5 days with vehicle and IAA94 and the number of spheres counted and then disaggregated. 1000 cells were the replated and allowed to generate
spheres for other 5 days (10 days) after then counted again, disaggregated and 1000 cells replated to form tertiary spheres for further 5 days (15 days).
et al., 2016). Epidemiological and preclinical studies
provided solid bases to start clinical trials for different
cancer histotypes, using metformin either as single or as
chemo/radio-sensitizing agent. Unfortunately, to date, no
clear results were attained in clinical studies, since antitumor
activity was identified only in few studies, whereas other
trials revealed inconsistent tumor responses (Gandini
et al., 2014; Kasznicki et al., 2014; Suissa, 2017; Tang et al.,
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FIGURE 8 | CLIC1 associated membrane current inhibition by biguanide compounds. Membrane current from GBM2 has been elicited by a 100 mV voltage step,
from –40 to +60 mV, 800 ms in duration. Stimulus has been delivered every 10 s to generate a current amplitude time course. CLIC1 current inhibition is calculated
as ratio of the effect induced by each compound and the inhibition observed after IAA94 (100 µM) treatment that represents the residual CLIC1 activity. For each
compound are shown experimental data at two different concentrations reported on the top of each current time course (left). The (right) depict box chart plots
showing the average inhibition of CLIC1 current, calculated as ratio between the compound and IAA94 sensitive currents. Number of cells used for the statistics
range from 4 to 8 for each compound concentration (empty circles next to box charts). Unpaired t-test: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001 vs. CTR cells.
2017). Despite several explanations were proposed for these
discrepancies, including pharmacokinetics and posology issues,
new studies are required to fully address the therapeutic
possibilities of metformin as novel antitumor agent as well
as to search and develop improved metformin derivatives.
Thus, metformin studies were redirected “from bed to bench.”
In particular, two main issues have been brought to the
attention of researchers: the high concentrations required to
obtain antitumor effects in vitro and the lack of a defined
mechanism by which metformin interferes with tumor cell
proliferation. This is particularly relevant for GBM, since,
among several other mechanism of action recently identified,
metformin was more often reported to exert antiproliferative
effects through the activation of AMPK and the subsequent
inhibition of mTOR, a mechanism shown to promote
GBM CSC growth (Chhipa et al., 2018; Leli and Koumenis,
2018). Thus a different intracellular mechanism should be
regulated by metformin, and possibly other biguanides, to
affect the proliferation and survival of this specific GBM cell
subpopulation.
In this study, searching for more efficacious and potent
metformin derivatives, we tested the effects of different
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FIGURE 9 | Effect of biguanides on the viability of cells in which CLIC1 associated membrane current is not relevant for cell proliferation. Concentration-response
curves of metformin (MET), phenformin (PHEN), cycloguanil (CG), moroxydine (MOR), and proguanil (PG) in differentiated GBM cells (A) and ucMSCs (B). Cell
viability was assessed by MTT reduction test, after 48 h of treatment. Data are the mean of n = 3 experiments performed in quadruplicate, on cells derived from 5
GBMs (for metformin: GBM1, 2, 3, 4, 6, 7) and 3 GBMs (for phenformin, cycloguanil, moroxydine, and proguanil: GBM2, 3, 4) and 4 independent ucMSC cultures.
For sake of clarity statistical significance is reported in Supplementary Table S1. The comparison of the effects of biguanides in GSCs and differentiated cells from
the same GBM is reported in Supplementary Figure S6.
TABLE 3 | Graphical representation of the pharmacological features of the different biguanides tested as antitumor agents, evaluating EFFICACY (maximal antiproliferative
effects), POTENCY (IC50), and SELECTIVITY (toxic effects induced via a mechanism independent from CLIC1 inhibition, occurring in cells different from GSCs).
COMPOUND
Metformin Phenformin Cycloguanil Moroxydine Proguanil
EFFICACY
POTENCY
SELECTIVITY
Green symbols mean high effects (bigger depending on the number of symbols), yellow symbols represent moderate effects, and red symbols indicate low activity.
biguanide-based molecules on GSC survival and/or proliferation,
invasiveness and self-renewal; we also evaluated the selectivity of
the biguanides toward tumor cells (and on the CSC component,
in particular) in comparison to normal stem cells, to verify the
safety profile as already reported for metformin. Specifically,
we searched for a common intracellular mechanism, targeted
by all the biguanides, underlying their antitumor effects, since
the identification of a pharmacological class-effect might pave
the way for novel, more potent and efficacious biguanide-
based drugs to be tested in the clinical setting. Our results
show that, beside metformin, other conformationally different
biguanide derivatives exert antiproliferative and anti-invasive
effects on GSCs, being also able to powerfully inhibit the
self-renewal (as for the spherogenesis assay) ability of this
GBM cell subpopulation, supporting their potential use as
repositioned antitumor agents. Although all these molecules are
known to act through the modulation of different intracellular
pathways, we observed that the inhibition of GSC proliferation
by all these drugs is mainly mediated by the blockade of
CLIC1 ion conductance, which we propose as main mechanism
of action responsible for the antitumor effects of all the
molecules containing a biguanide moiety. Interestingly, a similar
effect of metformin on CLIC1 activity was independently
reported in gallbladder cancer cells (Liu et al., 2017), further
confirming our evidence. At molecular level, we previously
reported that the biguanide moiety of metformin is able
to interact with a critical arginine (Arg29) in the CLIC1
putative pore region on the extracellular side, to prevent the
activation of the ion current (Gritti et al., 2014). Therefore, our
data support the hypothesis that CLIC1 inhibition represents
a pharmacological class-effect of compounds featured by a
biguanide substructure, which is the main determinant of cell
proliferation arrest. Thus, both linear (metformin, phenformin,
or moroxydine) or cyclized biguanides (cycloguanil) share
the same mechanism of CLIC1 inhibition. Interestingly, we
observed a rather significant relationship between the level
of CLIC1 inhibition and the antiproliferative activity exerted
by the drugs on GBM CSCs. For example, moroxydine,
showing the lower efficacy as GSC growth inhibitor (see
Table 2), caused only a partial blockade of the CLIC1-associated
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current. Conversely, a high inhibition of GSC proliferation,
as observed using metformin and cycloguanil, correlates with
a complete inhibition of CLIC1 activity, although the latter
drug was much more potent than the former one (IC50:
9.4 vs. 0.18 mM). Importantly, we observed that all the
compounds tested display a higher potency than metformin
to inhibit GBM CSC proliferation, reaching IC50 about 100-
fold lower. This observation suggests that these molecules
could be effective in vivo at more easily reachable doses.
Another difference among the compounds tested is the ability
of some of these drugs to promote GSC apoptosis. Phenformin
and cycloguanil caused a pro-apoptotic effect albeit modest
(+15 and +13%, respectively); moroxydine effects were even
lower, and not statistically significant in all the cultures.
Moreover, a pro-apoptotic activity was never observed in
metformin-treated cells. Since also CLIC1 inhibition induced
by IAA94 mainly results in mainly a cytostatic effect with
low level of induction of apoptosis in some cultures, we
hypothesize that although metformin is the more CLIC1-
selective drug among all the biguanides tested, also the
other compounds largely mimic the activity of the CLIC1
inhibitor.
Glioblastoma heterogeneity is a relevant issue for the
prognosis and the treatment options for this tumor. In fact,
recently, different GBM subtypes, based on molecular features
have been identified (Lieberman, 2017). Interestingly, although
the analysis is rather incomplete due to the limited number
of cases studied, we did not observe differences in the drug
response according to genetic characteristics of the GBMs
(i.e., MGMT promoter methylation, loss of PTEN, CDKN2a,
gain of EGFR, etc.). Although larger studies are required, this
observation suggest that the inhibition ofCLIC1 may represent
a target common to most GBM subtypes to impair CSC
proliferation.
We also compared the effects of biguanides on the
viability of differentiated GBM cells and ucMSCs, which
are not dependent on CLIC1 activity to proliferate. In fact,
in these cell types CLIC1 inhibition by IAA94 does not
reduce proliferation, and we previously reported that CLIC1
activity is almost undetectable, at least in the experimental
conditions adopted in our study (Gritti et al., 2014). Thus,
we assume that the effects observed in both differentiated
GBM cells and ucMSCs can be classified as “non-specific”
effects (i.e., CLIC1-independent toxic activity). In both these
cell populations, a “non-specific” inhibition of viability
was induced at all concentrations tested by proguanil,
which indeed is unable to inhibit CLIC1 activity, by high
concentrations of phenformin, and, at a lower extent, by
maximal cycloguanil concentrations. The occurrence of “non-
specific” cytotoxic effects might explain why phenformin,
although unable to completely block CLIC1 currents at
concentrations higher (i.e., 1 mM) than the antiproliferative
IC50 (0.35 mM), still causes high level of GSC viability
inhibition. Being the high specificity of metformin (and
moroxydine) toward GSCs (due to the selective CLIC1
inhibition) a likely determinant of its harmless effects in
normal cells (as demonstrated by its large use as frontline
antidiabetic drug), we propose that a higher specificity for CLIC1
inhibition might grant selected biguanides with lower unwanted
toxicities.
In agreement with this assumption, proguanil, which
resulted highly toxic in all the tested cell types (GSCs,
differentiated GBM cells, and ucMSC), showed a rather
non-specific (i.e., CLIC1-independent) mechanism of
action. This observation could appear in contrast with
the clinical use of this molecule as antimalarial drug.
However, it has to be pointed out that upon absorption
proguanil is partially converted to cycloguanil by liver
(Wangboonskul et al., 1993) and it is unlikely that the
concentrations we used in vitro can be reached in most
patients’ tissues. Moreover, off-target toxicities have been
reported in proguanil-treated individuals (mouth ulcers,
vasculitis, etc.). Notwithstanding, we analyzed proguanil in vitro
effects mainly to identify biguanide structures able or not to
exert a specific inhibition of CLIC1 activity. In particular,
from this analysis we observed that proguanil is not able to
inhibit CLIC1 activity, probably as a result of its chemical
structure, which combines the simultaneous presence of 1-
(4-chlorophenyl) ring and of the bulky 5-isopropyl group on
the rigid biguanide skeleton (see Figure 1A), thus possibly
preventing the access to CLIC1 pore in the extracellular
region.
In conclusion, we identified the inhibition of CLIC1 activity
as biguanide class-effect mediating antiproliferative effects in
GSCs. Considering the selective role of CLIC1 in controlling cell
cycle progression in GSCs (Verduci et al., 2017), we propose
that the broad antitumor activity of metformin and related
compounds, which has been reported in a high number of
different human tumors, might depend on the interference
with the chloride current associated to this protein. In fact,
since increased CLIC1 activity is a main regulator of cell
proliferation in several tumors, including gastric, colon, and
hepato-carcinomas (Peretti et al., 2015), and, of course, GBM
(Wang et al., 2012; Setti et al., 2013; Gritti et al., 2014), this
mechanism may reconcile the evidence of antitumor activity of
metformin (and possibly of other biguanides) on such broad
types of neoplasia.
Importantly, we identify several related molecules
which, although completely different from a structural
point of view (both linear and cyclized biguanides), show
higher potency than metformin, reaching as in the case of
cycloguanil, about 50-fold lower IC50, and possibly are able
to overcome the high concentrations required to induce
antiproliferative effects, the major limitation in metformin
clinical usefulness as anticancer drug. Furthermore, we
also characterized the tested biguanides for efficacy and
selectivity toward CLIC1 inhibition, to assess the occurrence
of possible off-target effects, likely responsible of unwanted
toxicities (Table 3). We believe that, although cycloguanil
display a slightly better profile as far as efficacy, potency
and specificity of the antitumor effects, no one of the
drugs tested meets, at best, all these features. However, the
establishment of a biguanide antitumor class-effect and
the identification of possible structural determinants of the
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antiproliferative activity of this family of drugs, will provide
the basis for the design and development of novel compounds
endowed with a better pharmacological profile (high potency
and low toxicity) which, in combination with already
approved cytotoxic drugs [i.e., temozolomide (Valtorta et al.,
2017)], might open a new perspective for this still incurable
tumor.
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